A carregar...
How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure
The evaluation and use of patient reported outcome (PRO) measures requires detailed understanding of the meaning of the outcome of interest. The Food and Drug Administration (FDA) recently presented its draft guidance and view on the use of PRO measures as endpoints in clinical trials. One section o...
Na minha lista:
Main Authors: | , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2006
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1599713/ https://ncbi.nlm.nih.gov/pubmed/17005037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7525-4-69 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|